CD79A and infection: However, commercial i/c-ELISA have not been validated for human brucellosis and SAT usefulness is limited by the fact that in brucellosis IgM/IgG/IgA agglutinating antibodies are progressively substituted following infection with IgG/IgA variants that are non-agglutinating [16,21–24].